Skip to main content

06-05-2021 | Semaglutide | News


FDA approves higher semaglutide dose for obesity

Author: Eleanor McDermid


medwireNews: The US FDA has approved the 2.4 mg weekly dose of semaglutide to treat obesity regardless of the presence of type 2 diabetes.

The dose is higher than the 1.0 mg weekly dose currently approved for reducing blood glucose levels in people with type 2 diabetes. The STEP 2 trial showed that the higher dose produces only a slight additional improvement in glycemic control, but a markedly larger reduction in bodyweight.

STEP 2 was the only trial in the STEP series to recruit people with diabetes; the others all enrolled people who had a BMI of 30 kg/m2 or of 25 kg/m2 with related comorbidities, but not diabetes. Four of these trials have published to date, with four still in progress.

The cardiovascular safety/efficacy study for semaglutide 2.4 mg/week, SELECT, is ongoing, with results expected in the second half of 2023.

The FDA notes that semaglutide 2.4 mg should not be used in combination with other glucagon-like peptide-1 receptor agonists, or with other products intended for weight loss, including prescription drugs, over-the-counter drugs, or herbal products.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video